Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A clinical diagnosis of a condition (cardiovascular and/or cerebrovascular protection or other reasons) that requires daily intake of low-dose ASA, 75-325 mg, and is expected to continue for the duration of the study (daily is defined as at least 5 days per week).
- • Age \>= 60 years.
- • No gastric and/or duodenal ulcer at the baseline endoscopy.
- • H. pylori negative by serology test at screening.
- Exclusion Criteria:
- • Upper GI symptoms
- • Erosive oesophagitis
- • Malignancy
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Budapest, , Hungary
Debrecen, , Hungary
Mainz, Rheinland Pfalz, Germany
Hamburg, , Germany
Mainz, , Germany
Cape Town, , South Africa
Lyttelton Manor, , South Africa
Parktown, , South Africa
Edinburgh, , United Kingdom
Pleven, , Bulgaria
Russe, , Bulgaria
Sofia, , Bulgaria
Varna, , Bulgaria
Quebec, , Canada
Wiesbaden, , Germany
Athens, , Greece
Ioannina, , Greece
Thessaloniki, , Greece
Hong Kong, , Hong Kong
Madrid, , Spain
Glasgow, , United Kingdom
Winnipeg, Manitoba, Canada
St. John's, Newfoundland And Labrador, Canada
Frankfurt, , Germany
Sudbury, Ontario, Canada
Cottbus, Brandenburg, Germany
Düsseldorf, Nordrhein Westfalen, Germany
Köln, , Germany
München, , Germany
Parma, Pr, Italy
Napoli, , Italy
Roma, , Italy
Sevilla, , Spain
Tygerberg, , South Africa
Ashford, South Australia, Australia
Hannover, , Germany
Granada, , Spain
Piraeus, , Greece
Gyula, , Hungary
Malvern, Victoria, Australia
Adelaide, , Australia
Bologna, , Italy
Kecskemét, , Hungary
Cardiff, , United Kingdom
Burgas, , Bulgaria
Potsdam, , Germany
Santiago De Compostela, A Coruña, Spain
North York, Ontario, Canada
Thornhill, Ontario, Canada
Ludwigshafen, , Germany
Oelde, , Germany
Ribnitz Damgarten, , Germany
Wolmirstedt, , Germany
Stuttgart, Baden Württemberg, Germany
Hannover, Niedersachsen, Germany
Halle, Sachsen Anhalt, Germany
Eger, , Hungary
Santiago, A Coruña, Spain
San Sebastián, Guipuzcoa, Spain
Gy¿R, , Hungary
Künzing, , Germany
Genova, Ge, Italy
Bay Roberts, Newfoundland And Labrador, Canada
Carbonear, Newfoundland And Labrador, Canada
Courcelette, Quebec, Canada
Miskolc, , Hungary
Oakville, Ontario, Canada
Parkdale, Prince Edward Island, Canada
Herne, , Germany
Lienen, , Germany
Lüdenscheid, , Germany
Münster, , Germany
Paderborn, , Germany
Wangen, , Germany
Vác, , Hungary
Carina Heights, Queensland, Australia
Murcia, , Spain
Woodville, South Australia, Australia
Bondi Junction, New South Wales, Australia
Bracken Ridge, Queensland, Australia
Wayville, South Australia, Australia
Ballarat, Victoria, Australia
Rostock, Mecklenburg Vorpommern, Germany
Siegen, , Germany
Wolfenbüttel, , Germany
Zeven, , Germany
Johannesurg, , South Africa
Irvine, Ayrshire, United Kingdom
Patients applied
Trial Officials
AstraZeneca Nexium Medical Science Director, MD
Study Director
AstraZeneca
Neville Yeomans, MD
Principal Investigator
Perth Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials